Exact Sciences stock is seeing consistent revenue growth, but the upside looks limited. Learn why investors need to pay close ...

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.

Exact Sciences is building a brand it hopes will become intimately linked with cancer testing. Once it does that, it will not need to spend as much on sales and marketing to attract customers.

Exact Sciences demonstrated exceptional financial discipline during Q3, delivering robust growth with lower operating expenditure. See why I rate EXAS a Buy.

Exact Sciences is building a cup without handle with a 72.83 buy point. See if it can clear the breakout price in volume at least 40% above average.

“The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin Conroy, Chairman and CEO of Exact Sciences.

Building upon decades of research, Exact Sciences intends to harness the additive sensitivity of multiple biomarker classes to detect more cancers in earlier stages.

Exact Sciences also recorded a 98.2% specificity rate, which means nearly all of the samples it flagged actually came from people known to have cancer.

Advancing New Solutions: Building on the success of the Cologuard and Oncotype DX tests, Exact Sciences continues to invest in its pipeline to develop innovative solutions for every stage of ...

Building upon decades of research, Exact Sciences intends to harness the additive sensitivity of multiple biomarker classes to detect more cancers in earlier stages.

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.